Sanofi Drug Shows Promise in Asthma After Blood Disorder Success [BNN Bloomberg (Canada)]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: BNN Bloomberg
The therapy, called rilzabrutinib, helped adults better control their asthma and alleviated symptoms in a mid-stage study, Sanofi said in a statement Wednesday. The results were positive for groups that received both a high dose and a low dose of the oral treatment during a 12-week study, with improvements seen as soon as the second week, Sanofi said. Sanofi is pushing a dozen potential top-selling medicines through costly clinical trials. Chief Executive Officer Paul Hudson has pointed to treatments like rilzabrutinib to justify his surprise decision in October to ramp up drug-development spending. The strategy shift caught investors off guard since it meant abandoning some older profit targets. Last month, Sanofi said rilzabrutinib had cleared a late-stage trial of patients with a rare blood disorder. A so-called BTK inhibitor, the drug targets cells in the body that play a critical role in the immune system. Sanofi is also testing the medicine in other immune-mediated diseases
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi: A Leader In Life-Saving Vaccines And Treatments [Seeking Alpha]Seeking Alpha
- Is It Too Late to Buy Novavax Stock? [Yahoo! Finance]Yahoo! Finance
- Exploring Dividend Stocks On Euronext Paris Featuring Exacompta Clairefontaine And Two Others [Yahoo! Finance]Yahoo! Finance
- Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Exploring Three Top Dividend Stocks On Euronext Paris [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 6/11/24 - Form 6-K
- 5/30/24 - Form 6-K
- 5/28/24 - Form 6-K
- SNY's page on the SEC website